The diagnosis of late-onset (age ≥50 years old) relapsing remitting multiple sclerosis (LORRMS) has been increasingly described in clinical practice, whereas data focusing on the specific therapeutic management of LORRMS are scarce. Our objective was to compare the effectiveness of injectable and oral first-line disease-modifying therapies (DMTs) in a cohort of LORRMS patients with time to first relapse, time to confirmed disability progression (CDP), and time to discontinuation.
First-line therapies in late-onset multiple sclerosis: An Italian registry study / Zanghì, Aurora; Avolio, Carlo; Amato, Maria Pia; Filippi, Massimo; Trojano, Maria; Patti, Francesco; D'Amico, Emanuele. - In: EUROPEAN JOURNAL OF NEUROLOGY. - ISSN 1351-5101. - 28:(2021), pp. 4117-4123. [10.1111/ene.15006]
First-line therapies in late-onset multiple sclerosis: An Italian registry study
Filippi, Massimo;
2021-01-01
Abstract
The diagnosis of late-onset (age ≥50 years old) relapsing remitting multiple sclerosis (LORRMS) has been increasingly described in clinical practice, whereas data focusing on the specific therapeutic management of LORRMS are scarce. Our objective was to compare the effectiveness of injectable and oral first-line disease-modifying therapies (DMTs) in a cohort of LORRMS patients with time to first relapse, time to confirmed disability progression (CDP), and time to discontinuation.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
